Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pacific Biomarkers Announces New Chief Scientific Officer

Published: Tuesday, January 03, 2012
Last Updated: Tuesday, January 03, 2012
Bookmark and Share
Pacific Biomarkers names the company's current Vice President, Research and Development, Amar A. Sethi, MD, PhD, as the new Chief Scientific Officer.

Dr. Sethi will succeed the current CSO and co-founder Elizabeth Teng Leary, PhD. Dr. Leary will assume a senior scientific advisory role while remaining active in scientific and business development activities at PBI.

Prior to joining the company, Dr. Sethi trained as a physician at the University of Copenhagen in Denmark (1996). In 2003 he was awarded a PhD in genetic epidemiology at the same institution, and in 2005 he became board certified in chemical pathology by the National Board of Health, Denmark. During 2005-2008 he was a postdoctoral fellow at the National Heart, Lung, and Blood Institute, Pulmonary and Vascular Medicine Branch, National Institutes of Health (NIH), and in 2008 he commenced a clinical chemistry fellowship in the Department of Laboratory Medicine, NIH, overseeing the Immunology Section while continuing his research. Dr. Sethi holds numerous awards and honors in both Denmark and the US, has presented extensively at international scientific meetings, and has published widely in international, peer-reviewed journals. His research has focused on genetic variations related to cardiovascular disease, and, most recently, on composition and function of HDL in patients with ischemic heart disease, and on apo-AI mimetic peptides in animal models of atherosclerosis. Currently, Dr. Sethi is focusing on innovative biomarkers to elucidate the role of HDL in cardiovascular disease.

Dr. Sethi was recently honored by R&D Directions as one of the "Most Notable People in R&D." R&D Directions' selection of the "Most Notable People in R&D" pays tribute to those who have led and made the significant breakthroughs in the discovery and development of drugs that indelibly change the ways in which particular diseases are treated.

"We are extremely pleased that a physician-scientist of Dr. Sethi's stature will be our CSO," commented Ron Helm, the company's CEO. "Amar is one of the leading scientists in the field and his work continues to reinforce our standing and reputation in the industry as the premier provider of esoteric testing services to pharma and diagnostic companies in the areas of cardiovascular, metabolic, and bone and joint diseases."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pacific Biomarkers, WuXi PharmaTech Announce Biomarker Collaboration
PBI will provide access to its extensive menu of validated biomarker assays to support WuXi's integrated clinical trial testing services.
Tuesday, March 11, 2014
Pacific Biomarkers' Dr. Amar A. Sethi Honored by Pharmaceutical Executive Magazine as One of 30 Emerging Pharma Leaders of 2011
Vice president of R&D called "A Pathfinder in Drug Development".
Wednesday, June 29, 2011
Scientific News
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!